Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00432458 · OUTCOME

Time to Treatment Failure

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma · Source last updated 2012-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
time from randomization to treatment failure (up to 5 years)

What was measured

Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method

Groups in this outcome

Arm I: Thal/ZLD

Thalidomide (Thal) + Zolendronic acid (ZLD)

Arm II: ZLD

Zoledronic acid (ZLD)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I: Thal/ZLD35
Arm II: ZLD33

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I: Thal/ZLD16.5Not reported9.527.6Not reported
Arm II: ZLD11.1Not reported8.416.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        9.5
        upper Limit
        27.6
        value
        16.5
      2. group Id
        OG001
        lower Limit
        8.4
        upper Limit
        16.7
        value
        11.1
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    2. group Id
      OG001
      value
      33
    units
    Participants
description
Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method
dispersion Type
95% Confidence Interval
groups
  1. description
    Thalidomide (Thal) + Zolendronic acid (ZLD)
    id
    OG000
    title
    Arm I: Thal/ZLD
  2. description
    Zoledronic acid (ZLD)
    id
    OG001
    title
    Arm II: ZLD
param Type
MEDIAN
reporting Status
POSTED
time Frame
time from randomization to treatment failure (up to 5 years)
title
Time to Treatment Failure
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice